Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935141 | 1.00 | PPARG (0.46) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL2641465 | 1.00 | PPARG (0.46) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL14935142 | 1.00 | PPARG (0.46) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL2641466 | 1.00 | PPARG (0.46) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL16705755 | 0.95 | SOAT2 (0.45) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL2641802 | 0.91 | FFAR1 (0.51) | PPARGPPARAFAAHFFAR1FFAR4 | |
| SCHEMBL2641799 | 0.91 | FFAR1 (0.51) | PPARGPPARAFAAHFFAR1FFAR4 | |
| SCHEMBL15027984 | 0.89 | ALOX5 (0.39) | PPARGSOAT2SOAT1EPHX2FAAH | |
| SCHEMBL23387064 | 0.89 | PPARG (0.41) | PPARGPPARASOAT2SOAT1PTGER4 | |
| SCHEMBL2636981 | 0.89 | FFAR1 (0.36) | PPARGPPARASOAT2SOAT1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-06-01 | — | — | US | disclosed |
| US-8865675-B2 | Compositions and methods for silencing apolipoprotein B | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2014-10-21 | — | — | US | disclosed |
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC (CA) | 2013-05-16 | — | — | US | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123338-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | PPARG 2474/4885PPARA 2052/4885SOAT2 552/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | PPARG 2474/4885PPARA 2052/4885SOAT2 552/4885 |
| US-20130123339-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | APOB, LDLR, APOL1 | PPARG 2479/4885PPARA 1182/4885SOAT2 539/4885 |
| US-20170151333-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | PPARG 2474/4885PPARA 2052/4885SOAT2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.